Bear, if the dosed patients are now at 2200 patient years, won't that imply that the Phase 3 trial is now at 4400 patient years at least?  I assume the 2200 patient years was of submission of the article to the journal.  So that could be 3 months back (I am just guessing here) which would imply even more patient years.  

More patient years is fantastic for RRR estimates as a) it increases the power of the trial dramatically from the 80% at 3600 patient years, b) allows that many more placebo MACE events to add up.